reports
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update...
Angi Inc. to Announce Q4 2025 Earnings on February 10th and Host Earni...
Angi Inc. to Announce Q4 2025 Earnings on February 10th and Host Earnings Conference Call on February 11th DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, February 10, 2026, Angi Inc. (NASDAQ: ANGI) will post its fourth quarter results and publish CEO Jeff Kip's letter to shareholders, which may include certain forward-looking information, at ir.angi.com/quarterly-earnings. On Wednesday, February 11, 2026, at 8:30 a.m. ET, Angi Inc. will host a conference call to answer questions regarding the company’s fourth quarter results. The live audiocast an...
Millennials Are Driving the Future of Home Spending, According to Angi...
Millennials Are Driving the Future of Home Spending, According to Angi’s State of Home Spending Report New data finds Millennials spend more per household on home projects overall than any other generation, reshaping how Americans maintain, upgrade, and live in their homes. DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- reveals that Millennials have become the primary drivers of today’s home projects economy, generating the highest total home spending per household of any generation. While Millennials are not yet the largest group of homeowners, they outspend all other generations on a per-...
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the ...
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 (esreboxetine) for the management of fibromyalgia. FORWARD (Fibromyalgia Response with Esreboxetine Evaluated Using a Randomized Withdrawal Research Design) is a Phase 3, double-blind, placebo-controlled, multicenter,...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year ...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY® preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively SUNOSI® preliminary 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively SYMBRAVO® preliminary 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively...
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Su...
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (NDA)...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 i...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly se...
- Carole Braudeau
Credit Morning 12/22/2025
Paris prosecutor's office launches probe into Uranium theft from Somaïr in Niger|Maxeda: weak Q3 results and announcement of restructuring process|Coty appoints Markus Strobel as new chairman and interim CEO|Golden Goose: HSG acquires majority stake|The Belgian government is considering increasing its stake in Ageas according to the Belgian newspaper de Tijd|
- Carole Braudeau
Morning Crédit 22/12/2025
Enquête du parquet de Paris sur le vol d’Uranium de la Somaïr au Niger|Maxeda : faibles résultats T3 et annonce du processus de restructuration|Coty nomme Markus Stroble comme nouveau Chairman et CEO par interim|Golden Goose : HSG acquiert une part majoritaire au capital|Le gouvernement belge envisageait d'augmenter sa participation dans Ageas selon le journal belge De Tijd|
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December: Piper Sandler 37th Annual Healthcare Conference Fireside Chat: Wednesday, December 3, 2025, at 4:00 p.m. ET in New York, NY BofA Securities CNS Therapeutics Virtual Conference 2025 Fireside Chat: Monday, December 8, 2025, at 11:40...
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positiv...
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has ente...
Angi Inc. Earnings Release and Letter to Shareholders Available on Com...
Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its third quarter financial results and a letter to shareholders from CEO, Jeffrey Kip on the investor relations section of its website at ir.angi.com/quarterly-earnings. As announced previously, Angi Inc. will host a conference call to discuss the company’s third quarter results and to answer questions. The call will be held on Wednesday, November 5, 2025, at 8:30 a.m. ET. Jeffrey Kip, CEO and Andrew Russakoff, CFO will participate...
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and P...
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer’s disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWI...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium Fireside Chat: Thursday, November 6, 2025, at 9:50 a.m. ET in New York, NY Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET i...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along wit...
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year’s theme for MIAW is “Building Community: Supporting Mental Well-being Together,” to highlight the import...
Angi Inc. to Announce Q3 2025 Earnings on November 4th and Host Earnin...
Angi Inc. to Announce Q3 2025 Earnings on November 4th and Host Earnings Conference Call on November 5th DENVER, Oct. 08, 2025 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, November 4, 2025, Angi Inc. (NASDAQ: ANGI) will post its third quarter results and publish CEO Jeff Kip's letter to shareholders, which may include certain forward-looking information, at ir.angi.com/quarterly-earnings. On Wednesday, November 5, 2025, at 8:30 a.m. ET, Angi Inc. will host a conference call to answer questions regarding the company’s third quarter results. The live audiocast and repl...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on ...
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live...
- Carole Braudeau
- Carole Braudeau
- Martin Marandon-Carlhian
- Stephane Houri
FP TOTAL SE
BVI BUREAU VERITAS SA
ADS ADIDAS AG
PUM PUMA SE
RI PERNOD RICARD SA
FORTUM FORTUM OYJ
KER KERING SA
HEI HEIDELBERGCEMENT AG
SY1 SYMRISE AG
CCL CARNIVAL PLC
ABI ANHEUSER-BUSCH INBEV SA/NV
KBX KNORR-BREMSE AG
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
CTPNV CTP NV
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.